OptMed(OMED)

从VEGF/DLL4双抗“三兄弟”的前世今生，分析双抗研发策略

同写意2022-05-14 21:40

撰文丨顾津明，同润生物CSO
编辑丨于靖
近日，Compass Therapeutics公布了其VEGF/DLL4（CTX-009）双特异抗体联合紫杉醇在治疗胆道癌（BTC）的2期临床中期研究成果，结果表明该双抗药物安全性良好，在24名患者中有10位病人平均治疗6个月后得到了客观缓解，ORR为42%（10/24），算不上惊艳，...查看全文

讨论

Horned_Reaper2019-04-23 19:41

$Oncomed制药(OMED)$ 查看全文

讨论

Horned_Reaper2019-03-09 00:21

$Oncomed制药(OMED)$ 0.848加点仓，希望可以像SEEL一样起飞查看全文

讨论

Horned_Reaper2019-02-28 05:25

$Oncomed制药(OMED)$ 看来要再洗掉几层皮！航班开始无限期延误...[好困惑]查看全文

讨论

Horned_Reaper2019-02-21 05:51

$Oncomed制药(OMED)$ 看来飞机超载，要洗一洗才能起飞查看全文

讨论

Horned_Reaper2019-02-16 02:56

$Oncomed制药(OMED)$ 晚了一点起飞查看全文

讨论

Horned_Reaper2019-01-07 22:55

$Oncomed制药(OMED)$ 请收起小桌板，调直座椅靠背，系好安全带！查看全文

讨论

Horned_Reaper2019-01-04 23:35

$Oncomed制药(OMED)$ 随时要起飞的节奏…查看全文

讨论

有为的股价小宝石2018-12-27 00:15

$Oncomed制药(OMED)$ 要开涨了啊查看全文

讨论

usbiostock2018-08-03 09:49

$OncoMed Pharmaceuticals, Inc. (OMED)$ 1. Navicixizumab单药治疗实体瘤临床1a期试验一线数据预计：2018年第4季度；2. Etigilimab单药治疗进展性/转移性实体瘤临床1a期试验一线数据预计：2018年第4季度；3. 现金：$79.9M。查看全文

其他

$OptMed(OMED)$ RW Registration Withdrawal Request Accession Number: 0000897069-23-000718  Act: NE  Size: 6 KB 网页链接

招股说明书「补充」

$OptMed(OMED)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001493152-22-020351  Act: 33  Size: 3 MB 网页链接

招股说明书

$Oncomed制药(OMED)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001493152-22-016871  Act: 33  Size: 44 MB 网页链接

公告

$Oncomed制药(OMED)$ 15-12B - Securities registration termination [Section 12(b)] Filed: 2019-05-03 AccNo: 0000950103-19-005954 Size: 11 KB 网页链接

公告

$Oncomed制药(OMED)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-04-26 AccNo: 0000921895-19-001178 Size: 202 KB 网页链接

公告

$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005050 Size: 22 KB 网页链接

公告

$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005051 Size: 22 KB 网页链接

公告

$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005052 Size: 22 KB 网页链接

公告

$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005053 Size: 22 KB 网页链接

公告

$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005054 Size: 22 KB 网页链接